News|Articles|November 16, 2026

FDA Approves Gefurulimab for Generalized Myasthenia Gravis

Author(s)Marco Meglio
Listen
0:00 / 0:00

Key Takeaways

  • Gefurulimab is a dual-binding nanobody C5 inhibitor whose albumin binding prolongs exposure, differentiating it from IV eculizumab and ravulizumab via weekly subcutaneous self-injection.
  • PREVAIL (n=260) met its primary endpoint with MG-ADL LS mean change −4.2 versus −2.6 (Δ −1.6; P<.001), with benefits evident by week 1 and sustained.
SHOW MORE

Gefurulimab (Klygefa), a once-weekly, self-administered complement C5 inhibitor from Alexion and AstraZeneca, is now approved in the US for adults with AChR-antibody-positive generalized myasthenia gravis.

The FDA has approved gefurulimab, marketed as Klygefa, for the treatment of adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive. The complement C5 inhibitor is dosed once weekly as a self-administered subcutaneous injection.1

Alexion describes Klygefa (gefurulimab-gaks) as the first and only dual-binding nanobody complement C5 inhibitor approved in the US; it binds C5 in the terminal complement cascade while its concurrent binding to serum albumin extends its half-life, enabling once-weekly dosing. The drug treats adults with gMG who test positive for AChR antibodies, a group that makes up about 85% of gMG patients, or roughly 81,000 of the estimated 98,500 people living with gMG in the US.

“[Klygefa] gives patients a targeted treatment option that empowers greater autonomy,” Kelly Gwathmey, MD, associate professor of neurology and chief of the neuromuscular division at Virginia Commonwealth University, and a principal investigator on the pivotal trial, said in a statement.1

Dosing consists of a weight-based loading dose on day 1, followed by weight-based maintenance doses starting on day 8 and continuing weekly, self-administered subcutaneously by autoinjector.

The phase 3 PREVAIL trial (NCT05556096) supported the approval. PREVAIL randomized 260 adults with AChR-antibody-positive gMG, 1:1, to gefurulimab or placebo across 113 sites in 20 countries, for a 26-week double-blind, placebo-controlled period. On the primary endpoint, gefurulimab reduced MG-Activities of Daily Living (MG-ADL) scores by a least-squares mean of 4.2 points, versus 2.6 points with placebo, a treatment difference of 1.6 points (95% CI, 0.8-2.4; P <.001).1,2

On the key secondary endpoint, the Quantitative Myasthenia Gravis (QMG) score improved by 4.5 points with gefurulimab versus 2.4 points with placebo, a difference of 2.1 points (95% CI, 1.1-3.1; P <.001), and 46.3% of gefurulimab-treated patients achieved a 5-point or greater QMG improvement, compared with 25.2% on placebo (P =.002). The Myasthenia Gravis Composite score also favored gefurulimab, with benefits on MG-ADL apparent by week 1 and on QMG and the composite score by week 4, sustained through week 26.2

During the 26-week randomized period, 75.6% of gefurulimab-treated patients and 80.6% of those on placebo experienced treatment-emergent adverse events, and no meningococcal infections occurred; gefurulimab-treated patients had injection site reactions more often, at 9.9% versus 3.1% with placebo.2 Klygefa carries a boxed warning for serious, life-threatening, or fatal meningococcal infections and is available only through a restricted REMS program requiring vaccination at least 2 weeks before the first dose.1

Across the full clinical program, including the open-label extension, 14% of gefurulimab-treated patients had injection site reactions, and 2 patients died of serious infections, dengue fever and sepsis following a dental infection; a separate serious Mycoplasma pneumoniae infection led to discontinuation, as did 3 serious diverticulitis cases involving intestinal perforation.

With the decision, gefurulimab becomes the third complement C5 inhibitor approved for gMG, following eculizumab in 2017 and ravulizumab in 2022, both of which require intravenous infusions every 2 to 8 weeks; gefurulimab's weekly subcutaneous self-injection is its main point of differentiation. Alexion CEO Marc Dunoyer called it "a first-of-its-kind treatment for gMG" built on the company's experience in C5 inhibition.1

“Today’s approval represents meaningful progress for people living with generalized myasthenia gravis,” Angela Lek, PhD, Chief Research Officer, Muscular Dystrophy Association, said in a statement.3 “Each new therapy brings us closer to more personalized and effective treatment approaches, offering renewed hope for improved quality of life and long-term disease management. We are encouraged by continued innovation that addresses the underlying biology of this disease.”

Alexion first reported positive PREVAIL results in 2026, and the European Medicines Agency's Committee for Medicinal Products for Human Use recommended gefurulimab's approval in September 2026, with a final European Commission decision still pending; submissions also remain under review in China and other countries.

A secondary analysis of PREVAIL presented at the 2026 AANEM Annual Meeting, discussed by lead investigator James Winkley, MD, found that gefurulimab-treated patients needed rescue therapy, such as intravenous immunoglobulin or plasmapheresis, less often than those on placebo, and had fewer MG-related hospitalizations, though the difference in clinical deterioration events between arms did not reach statistical significance. Winkley positioned gefurulimab as one of several mechanistically distinct options now available in gMG, alongside the FcRn inhibitors efgartigimod, rozanolixizumab, and nipocalimab, and suggested future combination regimens may eventually help patients who remain inadequately controlled on a single therapy.

REFERENCES
1. KLYGEFA™ (gefurulimab-gaks) approved in the US for the treatment of generalized myasthenia gravis (gMG) in adult patients. News release. Alexion, AstraZeneca Rare Disease. Published November 16, 2026. Accessed November 17, 2026. https://www.astrazeneca-us.com/media/press-releases/2026/KLYGEFA-gefurulimab-gaks-approved-in-the-US-for-the-treatment-of-generalized-myasthenia-gravis-gMG-in-adult-patients.html
2. Gwathmey KG, Saccà F, Howard JF Jr, et al. Efficacy and safety of gefurulimab in generalized myasthenia gravis: the PREVAIL phase 3 randomized clinical trial. JAMA Neurol. Published online July 27, 2026. doi:10.1001/jamaneurol.2026.2333
3. FDA Approves KLYGEFA™ (gefurulimab-gaks), Expanding Treatment Options for Generalized Myasthenia Gravis. Muscular Dystrophy Association. News release. November 16, 2026. Accessed November 16, 2026. https://www.mda.org/press-releases/fda-approves-klygefa-expanding-treatment-options-for-generalized-myasthenia-gravis

Related to this article